Wikipedia

User:Mr. Ibrahem/Tepotinib

< User:Mr. Ibrahem
Mr. Ibrahem/Tepotinib
Clinical data
Trade namesTepmetko
Other namesEMD-1214063
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: D[1]
  • Not recommended
Routes of
administration		By mouth
Legal status
Legal status
Identifiers
  • 3-{1-[(3-{5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin2-yl}phenyl)methyl]-6-oxo-1,6-dihydropyridazin3-yl}benzonitrile
Chemical and physical data
FormulaC29H28N6O2
Molar mass492.583 g·mol−1
3D model (JSmol)
  • CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1
  • InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3
  • Key:AHYMHWXQRWRBKT-UHFFFAOYSA-N

Tepotinib, sold under the brand name Tepmetko, is a medication used to treat non-small cell lung cancer (NSCLC).[3] Specifically it is used in metastatic disease that has mesenchymal-epithelial transition (MET) exon 14 skipping.[3] It is taken by mouth.[3]

Common side effects include swelling, tiredness, nausea, diarrhea, muscle pain, low sodium, and shortness of breath.[3] Other side effects may include pneumonitis and liver problems.[3] Use in pregnancy may harm the baby.[3] It is a kinase inhibitor that blocks MET.[3][7]

Tepotinib was approved in Japan in 2020, the United States in 2021, and Europe in 2022.[3][8][9] In the United Kingdom it costs the NHS about £7200 per month as of 2022.[9] This amount in the United States costs about 22,800 USD.[10]

References

edit
  1. ^ a b "Tepmetko APMDS". Therapeutic Goods Administration (TGA). 27 January 2022. Retrieved 5 February 2022.{{cite web}}: CS1 maint: url-status (link)
  2. ^ "Summary Basis of Decision (SBD) for Tepmetko". Health Canada. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
  3. ^ a b c d e f g h i j "Tepmetko- tepotinib hydrochloride tablet". DailyMed. Archived from the original on 27 November 2021. Retrieved 13 February 2021.
  4. ^ "FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer". Food and Drug Administration. 3 February 2021. Archived from the original on 3 February 2021. Retrieved 3 February 2021.   This article incorporates text from this source, which is in the public domain.
  5. ^ "Tepmetko EPAR". European Medicines Agency (EMA). 14 December 2021. Archived from the original on 5 May 2022. Retrieved 5 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  6. ^ "FDA Approves Tepmetko as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations". EMD Serono (Press release). 3 February 2021. Archived from the original on 4 February 2021. Retrieved 3 February 2021.
  7. ^ "Tepmetko". EMA. Archived from the original on 5 May 2022. Retrieved 31 October 2022.
  8. ^ "Tepmetko (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations" (Press release). Merck KGaA. 25 March 2020. Retrieved 3 February 2021.
  9. ^ a b "Tepotinib". SPS - Specialist Pharmacy Service. 17 September 2019. Archived from the original on 21 January 2022. Retrieved 31 October 2022.
  10. ^ "Tepmetko". Archived from the original on 31 October 2022. Retrieved 31 October 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Tepotinib&oldid=1233641439"